Medical/Pharmaceuticals
Fotona® Appoints Jeff Duchemin as Group President and CEO
Duchemin brings global MedTech leadership experience to accelerate Fotona's next phase of growth DALLAS , May 15, 2025 /PRNewswire/ -- FotonaⓇ, a global leader in high-performing laser systems and energy-based devices for aesthetic, dental and gynecological applications, today announces the app...
2025-05-15 23:00
4179
CIT Srl Charts a Visionary Path in Supply Chain Digitalization with TraceLink's Multienterprise Information Network Tower (MINT)
BOSTON, May 15, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, today announced thatCIT Srl, a rapidly growing contract packaging organization (CPO) based in the European Union, has selected TraceLink's Multienterprise In...
2025-05-15 22:00
2811
Alamar Biosciences Expands NULISAseq™ CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays
First-of-its-kind panel includes brain-derived pTau217, pTau181, pTau231, and total tau assays to advance neurodegenerative disease research FREMONT, Calif., May 15, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, tod...
2025-05-15 21:13
4287
STEERLife Redefines Potent Drug Development with Clean, Green, Continuous Processing
As a next-gen CRDMO, driving global pharma with continuous, solvent-free tech for potent drug development BENGALURU, India, May 15, 2025 /PRNewswire/ -- STEERLife, the life sciences division of STEER World, is advancing the development and manufacturing of potent and complex drug products. This...
2025-05-15 20:07
2245
Intalight™ Receives CE Mark for Its Progressive DREAM OCT™ Swept Source Imaging
SAN JOSE, Calif. and SHANGHAI, May 15, 2025 /PRNewswire/ -- Intalight™, a company that develops advanced ophthalmic technologies and a leader in Optical Coherence Tomography (OCT) today announced it has received CE mark for its DREAM OCT™ platform. The CE mark serves as approval by the European ...
2025-05-15 20:00
3639
STEERLife Redefines Potent Drug Development with Clean, Green, Continuous Processing
As a next-gen CRDMO, driving global pharma with continuous, solvent-free tech for potent drug development BENGALURU, India, May 15, 2025 /PRNewswire/ -- STEERLife, the life sciences division of STEER World, is advancing the development and manufacturing of potent and complex drug products. This...
2025-05-15 11:30
3098
Herbalgy Named Presenting Partner of Arsenal vs Tottenham Hotspur Match in Hong Kong
Exciting Rewards Await Fans
Download high-resolution images: https://cutt.ly/crzkcfZa
2025-05-14 21:31
3784
A NEW HOPE FOR PATIENTS SUFFERING FROM POTENTIALLY FATAL RARE HEART DISEASE: NUHCS IS FIRST IN ASIA TO RECRUIT PATIENTS FOR LANDMARK GENE EDITING CLINICAL TRIAL
The international study explores gene editing therapy to stop the production of proteins causing the disease in ATTR-CM patients SINGAPORE, May 14, 2025 /PRNewswire/ -- While receiving treatment for a car accident ten years ago, Mr Chua learnt that he had an abnormal build-up of protein in his ...
2025-05-14 16:20
4534
Clarivate Enhances OFF-X with Pathway Maps to Accelerate Target Safety Assessments
R&D teams can streamline safety evaluations, reduce risks and enable faster decision-making in drug development using new visual and data-driven insights LONDON, May 14, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the ...
2025-05-14 16:00
2683
Caliway Announces Successful EOP2 Meeting with the FDA for CBL-514 in Reduction of Abdominal Subcutaneous Fat
- Caliway has completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA for CBL-514, the world's first investigational drug for large-area subcutaneous fat reduction developed under the 505(b)(1) regulatory pathway. - The company has received the EOP2 meeting minutes, confirming the ...
2025-05-14 12:01
3951
Dupixent approved in Singapore as the first-ever biologic medicine for patients with COPD
* Following recent approvals in the EU, US and China, the Singapore approval is based on two replicate phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life compared to placebo. SING...
2025-05-14 10:30
2908
Novo Holdings Announces Investment in SCHOTT Poonawalla to Accelerate Growth and Innovation in Injectable Drug Packaging
SINGAPORE, May 14, 2025 /PRNewswire/ -- Novo Holdings, a global life sciences investor, today announced its investment in SCHOTT Poonawalla,India's leading provider of high-quality drug containment and delivery solutions for injectable pharmaceuticals, alongside TPG Growth, the middle market and ...
2025-05-14 09:00
3445
iotaMotion Announces First Use of Robotic-Assisted Cochlear Implant Technology Outside the U.S. as Part of Clinical Investigation in Switzerland
ST. PAUL, Minn., May 14, 2025 /PRNewswire/ -- iotaMotion, Inc., a leader in robotic-assisted systems for cochlear implant surgery, today announced the first use of the iotaSOFT® Insertion System outside of the United States. The technology is in use as a pre-market clinical investigation at Unive...
2025-05-13 23:51
2450
Rockwell Automation Launches PharmaSuite 12.00 to Accelerate Secure, Scalable Deployments
Latest MES release helps pharmaceutical and biopharmaceutical manufacturers
simplify system management, improve flexibility and speed time-to-value
MILWAUKEE, May 13, 2025 /PRNewswire/ -- Rockwell Automation, Inc.
2025-05-13 19:00
3508
Eligo Bioscience Awarded $5 Million to Advance Breakthrough Genetic Medicine Platform for Immuno-Dermatology
* Funding is part of the call for proposals "Innovations in Biotherapies and Bioproduction," coordinated by the Health Innovation Agency under France 2030 strategy, operated on behalf of the French government by Bpifrance PARIS, May 13, 2025 /PRNewswire/ -- Eligo Bioscience, a biotechnology com...
2025-05-13 17:00
3576
Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congress
SHANGHAI, May 13, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that updated results from the phase 2 study of irpagratinib (ABSK011) in combination with atezolizumab for the treatment of advanced hepatocellular carcinoma (HCC) will be presented at the 2025 ESMO G...
2025-05-13 11:38
6920
Waters Integrates Multi-Angle Light Scattering Detectors with Empower Software for Improved Biologics Quality Control and Simplified Regulatory Compliance
News Summary * Saves up to six months on compliant software validation in biopharmaceutical quality control.1 * Reduces analysis time for biotherapeutic peptides and proteins by 20%.2 * Enhances quality control by providing absolute molecular weight of biologics and avoiding common errors...
2025-05-13 08:00
3034
Improved Survival and Growth While Cutting Malnutrition for Premature Infants Fed Human Milk-Based Fortifiers at Sydney Hospital
Study Demonstrates Multiple Benefits of Prolacta's Exclusive Human Milk Diet Compared to Traditional Cow Milk-Based Feeding Protocol ADELAIDE, Australia, May 13, 2025 /PRNewswire/ -- Prolacta Bioscience®, the world's leading hospital provider of 100% human milk-based nutritional products, today...
2025-05-13 07:30
2458
Illuccix China Phase 3 Study Completes Enrolment
MELBOURNE, Australia and INDIANAPOLIS, May 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that the pivotal Phase 3 registration study of TLX591-CDx (Illuccix®, Kit for the preparation of68Ga-PSMA-11) for prostate cancer imagi...
2025-05-13 07:22
2998
Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS
YANTAI, China, May 12, 2025 /PRNewswire/ -- On May 12th, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that its phase 3 clinical trial (Study ID: RC48-C016) on disitamab vedotin (DV, brand name: 爱地希® ), the first domestically approved antibody-drug conjugate (ADC...
2025-05-12 16:29
6019
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00
Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21Nuix Neo Generative AI Framework
[Picked up by 262 media titles]
2026-10-08 08:02Ampotech and Buskowitz Energy Collaborate to Deliver Integrated Energy Solutions Combining Energy Efficiency, Solar and Battery Storage
[Picked up by 261 media titles]
2026-10-14 09:30
Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
13586
LEIFRAS Co., Ltd. Reports First Half of Fiscal Year 2026 Financial Results
2026-10-08 09:50
11416
XPENG G9L Completes First Production Trial in Europe
2026-10-08 07:33
11031
